retatrutide clinical trials retatrutide mechanism (RETA-10) 112mg Research Peptide Retatrutide, an experimental weight-loss drug,

Retatrutide acts as a triple incretin receptor agonist, simultaneously activating three distinct receptors: GLP-1 receptors stimulating insulin secretion in a glucose-dependent manner, slowing gastric emptying, and reducing appetite GIP receptors enhancing insulin release and potentially improving fat metabolism Glucagon receptors increasing energy expenditure and promoting fat breakdown in the liver This multi-receptor activity produces pronounced effects on body weight, blood glucose, lipid metabolism, and hepatic fat

Signs of a serious allergic reaction include hives, facial or throat swelling, severe dizziness, and difficulty breathing

1 The global anti-obesity drug market is expected to reach $82.55 billion (USD) by 2032, driven by a compound annual growth rate (CAGR) of 18.01% from 2025 to 2032

Y.CherepovA